FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US CSP FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US creativebharatgroup@gmail.com January 14, 2025 Stockholm, January 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today... Read More Read more about FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
